Finally, the IFN-regulated gene CD38 is repressed by Ikaros and Aiolos, and treatment with lenalidomide increased surface expression of CD38 in several MM cell lines leading to higher efficacy of ADCC mediated by daratumumab [168]. This evidence concerns the gene CD38 and Miyoshi myopathy.